XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.1
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net loss including noncontrolling interests in subsidiaries $ (163,718) $ (11,291)
Adjustments to reconcile net loss including noncontrolling interests in subsidiaries to net cash provided by (used in) operating activities:    
Change in fair value of investment, net 0 (4,108)
Loss (gain) on sale of investment (839) 3,316
Depreciation and amortization 1,897 1,064
Amortization of debt discount and issuance costs 702 0
Change in fair value of Series A redeemable convertible preferred stock embedded derivative 13,691 3,708
Change in fair value of Series A warrants 11,603 (958)
Change in fair value of Series B warrants 173,615 1,631
Non-cash stock compensation 450 332
Loss on foreign currency exchange 24 0
Change in fair value of equity securities (37,849) 6,005
Gain on sale of equity securities (819) 0
Earnings on equity investment in joint venture (2,730) 0
Changes in assets and liabilities:    
Accounts receivable (3,919) (110)
Prepaid expenses and other assets (843) (784)
Accounts payable and accrued expenses 2,332 (908)
Royalties and contingent legal fees payable 283 (108)
Net cash used in operating activities (6,120) (2,211)
Cash flows from investing activities:    
Patent acquisition (11,000) (5,780)
Sale of investment at fair value 3,591 905
Purchases of equity securities (9,200) (29,501)
Maturities and sales of equity securities 2,702 35,046
Purchases of property and equipment (33) (163)
Net cash (used in) provided by investing activities (13,940) 507
Cash flows from financing activities:    
Repurchase of common stock 0 (1,314)
Dividend on Series A Redeemable Convertible Preferred Stock (260) (263)
Issuance of Series B warrants 0 4,600
Paydown of Senior Secured Notes - short term (50,000) 0
Reissuance of Senior Secured Notes - short term 50,000 0
Net cash (used in) provided by financing activities (260) 3,023
(Decrease) increase in cash and cash equivalents and restricted cash (20,320) 1,319
Cash and cash equivalents and restricted cash, beginning 200,546 92,359
Cash and cash equivalents and restricted cash, ending 180,226 93,678
Supplemental schedule of noncash investing activities:    
Patent acquisition in exchange of notes receivable 4,000 0
Patent acquisition accrued liability - short term 10,000 0
Patent acquisition accrued liability - long term $ 5,000 $ 0